SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Medivation, Inc. and Astellas Pharma Inc. Announce XTANDI® (Enzalutamide) is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel